rfth-1 Antibody

What is RFTN1 and what is its role in cellular biology?

RFTN1 (raftlin, lipid raft linker 1) is a major raft protein with a molecular mass of approximately 63 kDa that was originally identified in B cells. It colocalizes with B-cell receptor (BCR) in lipid rafts both before and after BCR activation. RFTN1 contains fatty acylation sites at its N-terminus and predominantly localizes in the cytoplasm of human epithelial cells and monocyte-derived dendritic cells (Mo-DCs) . The protein plays a crucial role in maintaining lipid raft integrity and is involved in various cellular signaling pathways.

What are the validated applications for RFTN1 antibody?

The RFTN1 antibody (24289-1-AP) has been validated for multiple experimental applications:

The antibody shows positive WB detection in HeLa and Raji cells, and positive IHC detection in human tonsillitis and spleen tissues .

How should I design validation experiments for antibody specificity?

Proper antibody validation is critical for ensuring research reproducibility. A comprehensive validation approach should include:

• Specificity controls: Include positive and negative controls. For RFTN1 antibody, HeLa and Raji cells can serve as positive controls .

• Multiple detection methods: Confirm results using at least two independent techniques (e.g., WB and IHC).

• Genetic approaches: Use knockout/knockdown systems to verify antibody specificity. Research has documented RFTN1 antibody utility in knockdown experiments .

• Cross-reactivity testing: Test against similar proteins or in samples where the target protein is absent.

• Quantitative analysis: Compare antibody binding with protein expression levels.

Remember that approximately 50% of commercial antibodies fail to meet basic characterization standards, which can severely impact experimental reliability .

What are the common challenges when using RFTN1 antibody in Western blotting?

When performing Western blotting with RFTN1 antibody, researchers may encounter several challenges:

• Molecular weight variations: While the calculated molecular weight of RFTN1 is 63 kDa, the observed molecular weight ranges from 63-70 kDa . This variation could be due to post-translational modifications or different isoforms.

• Detection sensitivity: The recommended dilution range for Western blotting is 1:1000-1:4000 . Optimization may be necessary for your specific sample type.

• Background signals: Non-specific binding can obscure results. Proper blocking and washing steps are essential.

• Sample preparation: RFTN1's association with lipid rafts may require specific lysis conditions to ensure complete extraction.

To address these issues, perform careful titration of antibody concentration, optimize blocking conditions, and include appropriate controls in each experiment.

How can I optimize immunohistochemistry protocols for RFTN1 detection?

For optimal RFTN1 detection in IHC applications:

• Antigen retrieval: The recommended method is TE buffer at pH 9.0, although citrate buffer at pH 6.0 can also be used as an alternative .

• Antibody dilution: Start with the recommended range of 1:50-1:600 and optimize for your specific tissue.

• Positive control tissues: Human tonsillitis and spleen tissues have been validated as positive controls .

• Detection system selection: Choose a detection system appropriate for rabbit IgG antibodies.

• Incubation conditions: Optimize temperature and duration of primary antibody incubation.

Remember that each experimental system may require specific optimization to obtain reliable results.

How can I investigate RFTN1's role in lipid raft organization using antibody-based techniques?

To study RFTN1's function in lipid raft organization:

• Co-immunoprecipitation: Use RFTN1 antibody for IP to identify interacting proteins within lipid rafts.

• Co-localization studies: Perform dual immunofluorescence with RFTN1 antibody and other lipid raft markers.

• Lipid raft isolation: Combine detergent-resistant membrane isolation with Western blotting using RFTN1 antibody.

• Proximity ligation assay: Investigate protein-protein interactions involving RFTN1 in situ.

• Live cell imaging: Use fluorescently-tagged antibody fragments to track RFTN1 dynamics in living cells.

These approaches can help elucidate RFTN1's role in organizing lipid raft domains and its involvement in signaling pathways.

What controls should I include when using RFTN1 antibody in complex experimental designs?

For robust experimental design with RFTN1 antibody:

• Isotype controls: Include rabbit IgG (matching the RFTN1 antibody isotype) to identify non-specific binding.

• Blocking peptide controls: Use the immunogen peptide (RFTN1 fusion protein Ag17264) to confirm binding specificity.

• Genetic controls: Include RFTN1 knockdown/knockout samples as negative controls.

• Multiple antibody validation: Cross-validate results with another RFTN1 antibody targeting a different epitope.

• Cross-species controls: If studying conserved functions, include samples from different species as specificity controls.

Remember that antibody characterization is critical for enhancing reproducibility in biomedical research, as highlighted by recent initiatives addressing the "antibody characterization crisis" .

How does RFTN1 antibody performance compare to other lipid raft protein detection methods?

When comparing RFTN1 antibody-based detection to other approaches:

• Sensitivity and specificity: RFTN1 antibody provides specific detection with moderate sensitivity compared to mass spectrometry-based approaches.

• Spatial information: Unlike biochemical fractionation methods, immunofluorescence with RFTN1 antibody provides spatial information about raft localization.

• Temporal resolution: Antibody-based live imaging offers better temporal resolution than biochemical methods.

• Quantification limitations: Western blotting with RFTN1 antibody provides semi-quantitative data compared to more precise quantitative proteomics.

• Multiplexing capacity: Newer multiplexed antibody techniques allow simultaneous detection of RFTN1 with other raft components.

How should I interpret discrepancies between RFTN1 antibody results and other experimental data?

When facing contradictory results:

• Antibody validation: Verify RFTN1 antibody specificity using the recommended controls and dilutions (WB: 1:1000-1:4000; IHC: 1:50-1:600) .

• Technical differences: Consider how different detection methods might influence results (e.g., fixation can alter epitope accessibility).

• Biological variability: Evaluate whether differences reflect true biological variation in RFTN1 expression or localization.

• Post-translational modifications: Determine if modifications affect antibody recognition.

• Isoform specificity: Assess whether the antibody detects all relevant RFTN1 isoforms.

Thorough documentation and reporting of antibody characteristics are essential for resolving discrepancies, as emphasized by recent efforts to enhance antibody validation standards in scientific research .

What emerging technologies are enhancing RFTN1 antibody-based research?

Several cutting-edge approaches are advancing RFTN1 antibody applications:

• AI-designed antibodies: Recent breakthroughs in AI-driven protein design, such as RFdiffusion, are enabling the creation of highly specific antibodies with atomic precision .

• Single-cell antibody profiling: Techniques for analyzing RFTN1 expression at the single-cell level are providing unprecedented resolution of cellular heterogeneity.

• Proximity-dependent labeling: Methods combining RFTN1 antibodies with proximity labeling enzymes allow systematic mapping of the lipid raft interactome.

• Super-resolution microscopy: Advanced imaging techniques are enabling visualization of RFTN1 within nanoscale lipid raft domains.

• Antibody engineering: Development of smaller antibody fragments and nanobodies against RFTN1 is improving tissue penetration and reducing background.

The fine-tuned AI models for generating functional antibodies, as demonstrated by the Baker Lab's RFdiffusion technology, represent a significant advancement that may impact future RFTN1 research .

How can I integrate RFTN1 antibody data with other omics approaches?

For comprehensive multi-omics integration:

• Correlation analysis: Compare RFTN1 protein levels (detected by antibody) with transcriptomic data for RFTN1 and associated genes.

• Pathway enrichment: Contextualize RFTN1 antibody findings within relevant signaling pathways using pathway analysis tools.

• Interactome mapping: Combine RFTN1 antibody-based interactome data with publicly available protein-protein interaction databases.

• Functional validation: Use RFTN1 antibodies in functional assays to validate predictions from genomic or transcriptomic studies.

• Spatial transcriptomics integration: Correlate spatial distribution of RFTN1 protein (from antibody staining) with spatial transcriptomics data.

This integrated approach provides a more complete understanding of RFTN1's biological context and functional significance.